-
Mashup Score: 2IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma - 1 month(s) ago
During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Handling GI Toxicities While Using Selinexor Triplet Therapy in RRMM - 2 month(s) ago
Adam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Paula Rodriguez-Otero, MD, PhD, provides an overview of the phase 3 KarMMa-3 trial of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2CART-ddBCMA Achieves 100% Response Rate in RRMM - 3 month(s) ago
Matthew J. Frigault, MD, MS, discussed follow-up data on the efficacy and safety of CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma, particularly in later-line settings.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Isa-EloPD is Safe and Feasible in R/R Multiple Myeloma - 3 month(s) ago
Binod Dhakal, MD, MS, discusses the safety data from the phase 2 IMPEDE study of isatuximab, pomalidomide, elotuzumab, and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1CART-ddBCMA Achieves 100% Response Rate in RRMM - 4 month(s) ago
Matthew J. Frigault, MD, MS, discussed follow-up data on the efficacy and safety of CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma, particularly in later-line settings.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1KarMMA-3: Ide-Cel vs Standard Regimens in Triple-Class–Exposed RRMM - 4 month(s) ago
Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
During a Targeted Oncology™ Clinical Case Forum event in partnership with the South Carolina Oncology Society, Hamza Hashmi, MD, discusses the significance of the MajesTEC-1 of the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
During a Targeted Oncology™ Clinical Case Forum event in partnership with the South Carolina Oncology Society, Hamza Hashmi, MD, discusses the significance of the MajesTEC-1 of the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Belantamab Mafodotin Plus BorDex Improves PFS in RRMM - 5 month(s) ago
The phase 3 DREAMM-7 trial met its primary end point of progression-free survival, and overall survival data is trending positively.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. #RRMM #MMSM | @DukeMedSchool https://t.co/HvnMZ33eNq